SCHEMBL1636364

SCHEMBL1636364

CCCN(CCC)CCCCNC(=S)Nc1ccc(CN(Cc2ncc[nH]2)C(C)c2ncc[nH]2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 3/20 0.45
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
KMT2A Q03164 6/20 0.37
KDM4E B2RXH2 5/20 0.37
HTT P42858 5/20 0.37
MEN1 O00255 5/20 0.37
RAD52 P43351 3/20 0.37
ALDH1A1 P00352 3/20 0.37
GLA P06280 1/20 0.37
QPCT Q16769 1/20 0.37
LMNA P02545 4/20 0.35
PABPC1 P11940 1/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
MAPT P10636 2/20 0.34
GAA P10253 2/20 0.34
HPGD P15428 1/20 0.33
NFKB1 P19838 1/20 0.33
NFKB2 Q00653 1/20 0.33
RELA Q04206 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1638133 0.90 CXCR4 (0.51) CXCR4RAB9ALMNAMAPTFPR2
SCHEMBL1637072 0.85 CXCR4 (0.46) CXCR4ALDH1A1SMN1; SMN2FPR2
SCHEMBL1205352 0.84 CXCR4 (0.55) CXCR4RAB9AKMT2A
SCHEMBL1205930 0.83 CXCR4 (0.62) CXCR4GLALMNASMN1; SMN2
SCHEMBL1637426 0.82 CXCR4 (0.49) CXCR4
SCHEMBL1205303 0.81 CXCR4 (0.47) CXCR4GLALMNASMN1; SMN2
SCHEMBL1206163 0.81 CXCR4 (0.58) CXCR4KMT2AKDM4EMEN1GLA
SCHEMBL1206704 0.81 CXCR4 (0.49) CXCR4RAB9AKMT2AKDM4EALDH1A1
SCHEMBL1637267 0.80 CXCR4 (0.55) CXCR4NPC1RAB9AKMT2AKDM4E
SCHEMBL1292672 0.80 CXCR4 (0.49) CXCR4GLALMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110172212-A1 AMINE-BASED COMPOUND AND USE THEREOF KUREHA CORPORATION (JP) 2011-07-14 US claimed
US-20070208007-A1 Amine-Based Compound and Use Thereof KUREHA CORPORATION (JP) 2007-09-06 US claimed
EP-1724263-A1 BASIC AMINE COMPOUND AND USE THEREOF Kureha Corporation (JP) 2006-11-22 EP claimed
EP-1724263-B1 BASIC AMINE COMPOUND AND USE THEREOF KUREHA CORP (JP) 2014-03-05 EP disclosed
US-20110172212-A1 AMINE-BASED COMPOUND AND USE THEREOF KUREHA CORPORATION (JP) 2011-07-14 US disclosed
US-7932281-B2 Amine-based compound and use thereof KUREHA CORPORATION (JP) 2011-04-26 US disclosed
US-20070208007-A1 Amine-Based Compound and Use Thereof KUREHA CORPORATION (JP) 2007-09-06 US disclosed
EP-1724263-A1 BASIC AMINE COMPOUND AND USE THEREOF Kureha Corporation (JP) 2006-11-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172212-A1 AMINE-BASED COMPOUND AND USE THEREOF NR0B2, NR5A2, NR1D2 CXCR4 86/4885NPC1 1975/4885RAB9A 3790/4885
US-20070208007-A1 Amine-Based Compound and Use Thereof NR0B2, NR5A2, NR2E1 CXCR4 100/4885NPC1 1290/4885RAB9A 3885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.